Sangdunchoi:company

• Home
• Professor
• Lab Members
• Projects
• Publications
• Alumini
• Photos
• Join Us
• S&K Therapeutics

S&K Therapeutics We will provide patients with better life opportunities by developing therapeutic agents for immune diseases. About snktherapeutics.com S&K Therapeutics owns an AI-based drug development platform that allows us to discover new molecular entities effectively. Furthermore, based on extensive research experience on TLRs (Toll-like receptors), S&K therapeutics is establishing new drug development pipelines for autoimmune diseases, inflammatory diseases, and viral diseases. Vision S&K Therapeutics is focusing its core capabilities on developing new small molecule drugs to meet the unmet medical needs, and aims to develop new medicine for lupus, RA, psoriasis, Alzheimer's, and diabetes. Plarform Technology Artificial Intelligence for Development of New Drugs Solid Basic Research & Development TLR Target New Drug Discovery-POC Study, MOA Study Global License Out Open Innovation & Technology IP Transfer CEO Career Dean of College of Natural Sciences, Ajou University, Korea (2018 ~ present) Adjunct Professor in Rheumatology Department, Ajou University Medical School (2015 ~ present) Professor in Dept. of Molecular and Science and Technology, Ajou University (2006 ~ present) Transcriptome Analysis Lab Director, California Institute of Technology, USA (1997-2006) Platform Technology S&K is a new drug development platform that mainly focuses on the lead compound discovery using artificial intelligence and computational techniques. S&K implements the innovative technology that can reduce the total duration of drug development from 10 years to 5 years. Target The TLR (Toll-like receptor) is one of the major factors in the pathogenesis of lupus. TLR signaling pathway plays a crucial role in the activation of innate immune responses, which is the first line of defense against external/foreign substances. TLR immediately responds to the invading pathogenic substances and secretes various cytokines to help the development of acquired immunity. However, if TLR signaling is over-activated, it can cause autoimmune or inflammatory diseases such as systemic lupus erythematosus or rheumatoid arthritis, which can be treated by directly blocking the signal transduction of the TLR. R&D INDICATION Lupus is a disease that causes inflammatory reactions due to autoimmunity, which has various symptoms such as skin rash, photosensitivity, arthritis, canker sores, nephritis, hematocytopenia, angitis and hydrohymenitis. LUPUS The reduction of lupus markers and inflammatory cytokines in lupus animal models. RHEUMATOID ARTHRITIS Reduction of RA indicators in the animal model and confirmation of the effect in tissue and joint recovery. PIPELINE Six new drug pipelines (SLE) and 2 new drug candidates (RA) in the progress of optimizing Completion of patent applications (Korean Intellectual Property Office) & PCT applications S&K News Korean researchers have made great progress in developing treatments for autoimmune and inflammatory diseases. When will the systemic lupus erythematosus cure come out? Notice Contact Woncheon hall 136, Ajou University, Worldcup-ro 206, Yeongtong-gu, Suwon-si, Gyeonggi-do, 16499, Republic of Korea Tel : +82 10 9098 3629 e-mail : yunsangyong@gmail.com We will provide patients with better life opportunities by developing therapeutic agents for immune diseases.